In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RP Scherer Corp.

Division of Cardinal Health Inc.
www.rpscherer.com

Latest From RP Scherer Corp.

Vectura Ltd.

Given the need to find more effective, and faster, ways of administering a widening range of drugs, many companies are looking to improve pulmonary drug delivery. One of Vectura's goals is improving existing dry powder inhalation systems.
BioPharmaceutical

Alkermes' Incrementalism

Alkermes' success in creating a commercial product out of Genentech's growth hormone has taken it across a fundamental credibility gap all new drug delivery companies face. One result: an extraordinarily high valuation that has permitted it to raise plenty of cash. And it's using these assets--credibility, cash and valuation--to invest in programs which can bring it nearer term revenues and higher margins, in terms of new, accelerated, or risk-sharing deals. Indeed, it's even treating its current net-loss position as an asset, spending heavily now--which its profitable competitors can't, given their valuation-sensitive earnings constraints--and even signing complex deals to take its partners' expenses onto its own P&L, reimbursing itself with equity and downstream milestones. Moreover, it's shown itself, as in its acquisition of Advanced Inhalation Research, willing to dramatically expand its portfolio of technologies with work done on the outside. Alkermes also wants to develop products for its own account, though its strategy for commercializing them, while maintaining a strong delivery technology base, is unclear.
BioPharmaceutical Business Strategies

Yamanouchi's Foray Into Drug Delivery

Yamanouchi attempts to use its drug delivery business (Yamanouchi Shaklee Pharma) to help jumpstart its efforts to gain a foothold in the US and to eventually become a true global player. Yamanouchi's support of YSP may, however, be a two-edged sword: it provides YSP with the kind of financial support that most drug delivery companies can only dream of, but it may also scare off potential partners.
BioPharmaceutical North America

Why the Drug Delivery Industry Can Consolidate

Drug delivery companies have been consolidating with a fury over the last twelve months, unlike biotechs. The difference: delivery firms have plenty of drug service companies to sell to (other drug delivery firms, distributors, generic houses), while biotechs can only sell to Big Pharma--which doesn't want to buy them.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cardinal Health Inc.
  • Senior Management
  • John Lowry, Pres.
    Patricia McCullough, VP, Pharmaceutical Sales & Mktg.
    David Savello, PhD, EVP, CTO
  • Contact Info
  • RP Scherer Corp.
    Phone: (908) 580-1500
    645 Martinsville Rd.
    Ste. 200
    P.O. Box 7060 Basking Ridge, NJ 07920
    USA
UsernamePublicRestriction

Register